WESTLAKE, Ohio, Aug. 4 /PRNewswire/ -- Radiometer today announced it has received 510(k) clearance from the U.S. Food and Drug Administration for its ABL80 FLEX CO-OX, a portable blood gas analyzer that brings speed and simplicity to the point-of-care. The company expects commercial release of the instrument to soon follow.
Benchtop performance in a small package
The ABL80 FLEX CO-OX accurately measures pH, blood gases, electrolytes, glucose and vital CO-oximetry parameters. CO-oximetry provides critical information to the clinician for assessment of the acutely ill patient's oxygen status, including oxygen uptake, transport and release.
The ABL80 FLEX CO-OX matches the CO-oximetry performance of Radiometer's benchtop analyzers, representing Radiometer's commitment to providing quality solutions for both laboratory and point-of-care testing.
Advanced CO-oximetry
Radiometer's sophisticated CO-oximetry technology utilizes multi-wavelength technology for high measurement performance combined with an ultrasonic hemolyzation process. Ultrasonic hemolyzation offers advantages over chemical hemolyzation, including low maintenance and zero risk of interference from chemical hemolyzing agents or partially hemolyzed red blood cells.
About Radiometer
Radiometer is a world leader in the development, manufacture and distribution of technologically advanced acute care testing solutions. Radiometer's products and services simplify and automate all phases of acute care testing, so hospitals can get fast results, reduce workload and the risk of errors, and improve cost effectiveness. For more information, visit www.radiometeramerica.com .
CONTACT: Jan Weaver, Marketing Services Manager, Radiometer America Inc.,
+1-440-871-8900, ext. 262, jweaver@radiometeramerica.com
Web site: http://www.radiometeramerica.com/
